Brief: Spero Therapeutics Closes Exclusive License Agreement With GSK For Tebipenem HBr
08/11/2022 13:34
Nov 8 (Reuters) - GSK plc GSK.L :
* SPERO THERAPEUTICS ANNOUNCES CLOSING OF EXCLUSIVE LICENSE
AGREEMENT WITH GSK FOR TEBIPENEM HBR
Source text for Eikon: ID:nGNX4FwC5j
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)